KRASCENDO 3

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

May 10, 2026 → Oct 31, 2026

Cited window

May 10, 2026 → Oct 19, 2026

Retrieved

Nov 1, 2026

Title

A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer

Registry

NCT07541170

Study IDs

BO45885 · 2025-524263-21-00

Sponsor

Hoffmann-La Roche

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

400 estimated

Registered

2026-04-21

Start

2026-10-06 actual

Primary completion

2032-01-31 estimated

Primary endpoint

Disease-free Survival (DFS), as Determined by the Investigator

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The views come from the sources reviewed for this edition, not a representative sample of HCP opinion. Multiple posts discuss the same NAUTIKA1 cohort and should not be counted as independent clinical evidence.
• –Coverage concentrated on the trial identifier and known names. Unnamed references and different transcriptions may be missing, and several potentially relevant passages have not been fully assessed.
• –No publication reporting NCT07541170 was identified, no separate protocol document was listed in the registry, and no exact divarasib regulatory label was found. These absences do not establish publication or regulatory status.
• –The substantive activity, surgical-feasibility and tolerability observations concern a small neoadjuvant phase II NAUTIKA1 cohort, not randomized postoperative KRASCENDO3 outcomes.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –A speaker's statement relays another party's early-stage perspective; it should not be treated as his own regimen-specific recommendation.

How reports are built and checked: Methods.

Last checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "KRASCENDO 3" (NCT07541170), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "krascendo-3-07541170". If you cannot make requests, read https://www.erudio.com/reports/krascendo-3-nct07541170.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07541170", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07541170 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/krascendo-3-nct07541170.json
curl https://www.erudio.com/reports/krascendo-3-nct07541170.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "krascendo-3-07541170" })